News Daily News Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths Michael O'Riordan December 08, 2022
News Daily News Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says Todd Neale December 08, 2022
News Conference News AHA 2022 STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends Todd Neale November 07, 2022
News Conference News AHA 2022 IRONMAN Misses but Lends Support to IV Iron Repletion in HF Shelley Wood November 05, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News AHA 2022 Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions Yael L. Maxwell November 01, 2022
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News TCT 2022 HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza Todd Neale September 16, 2022
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for August 2022 Shelley Wood September 01, 2022
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News TVT 2022 Non-COAPT-Like Patients Fare Well With MitraClip, EXPAND Suggests Michael O'Riordan June 09, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022